The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial

JACC: Cardiovascular Interventions

Volumn 9, Issue 12, 2016, Pages 1231-1242

  Suwannasom, Pannipa ^a,b,c   Sotomi, Yohei ^b   Ishibashi, Yuki ^a   Cavalcante, Rafael ^a   Albuquerque, Felipe N ^d   Macaya, Carlos ^e   Ormiston, John A ^f   Hill, Jonathan ^g   Lang, Irene M ^h   Egred, Mohaned ⁱ   Fajadet, Jean ^j   Lesiak, Maciej ^k   Tijssen, Jan G ^b   Wykrzykowska, Joanna J ^b   de Winter, Robbert J ^b   Chevalier, Bernard ^l   Serruys, Patrick W ^m   Onuma, Yoshinobu ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ FREEMAN HOSPITAL   (United Kingdom)

^j Department of Ophthalmology   (France)

^k POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^l Institut Jacques Cartier   (France)

^m NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

asymmetry; bioresorbable vascular scaffolds; eccentricity; expansion

Indexed keywords

ADULT; ARTICLE; BIORESORBABLE SCAFFOLD; CLINICAL OUTCOME; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; CORONARY STENTING; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METAL STENT; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; ADVERSE EFFECTS; AGED; BIODEGRADABLE IMPLANT; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; CORONARY DISEASE; DEVICES; DIAGNOSTIC IMAGING; DRUG ELUTING STENT; INTERVENTIONAL ULTRASONOGRAPHY; LEAST SQUARE ANALYSIS; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSTHESIS DESIGN; RISK FACTOR; STENT; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

CARDIOVASCULAR AGENT; EVEROLIMUS; METAL;

ABSORBABLE IMPLANTS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METALS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SINGLE-BLIND METHOD; STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84976521324     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.03.027     Document Type: Article

References (27)

1. 1 Onuma, Y., Serruys, P.W., Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?. Circulation 123 (2011), 779–797.
2. 2 Ellis, S.G., Kereiakes, D.J., Metzger, D.C., et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 373 (2015), 1905–1915.
3. 3 Serruys, P.W., Chevalier, B., Dudek, D., et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385 (2015), 43–54.
4. 4 Ormiston, J.A., Webber, B., Ubod, B., Darremont, O., Webster, M.W., An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention 11 (2015), 60–67.
5. 5 Brugaletta, S., Gomez-Lara, J., Diletti, R., et al. Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 79 (2012), 219–228.
6. 6 de Jaegere, P., Mudra, H., Figulla, H., et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 19 (1998), 1214–1223.
7. 7 Otake, H., Shite, J., Ako, J., et al. Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. J Am Coll Cardiol Intv 2 (2009), 459–466.
8. 8 Diletti, R., Serruys, P.W., Farooq, V., et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 164 (2012), 654–663.
9. 9 Serruys, P.W., Onuma, Y., Ormiston, J.A., et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122 (2010), 2301–2312.
10. 10 Gomez-Lara, J., Diletti, R., Brugaletta, S., et al. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. EuroIntervention 8 (2012), 214–224.
11. 11 Farooq, V., Gomez-Lara, J., Brugaletta, S., et al. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. Catheter Cardiovasc Interv 79 (2012), 880–888.
12. 12 Ishibashi, Y., Nakatani, S., Sotomi, Y., et al. Relation between bioresorbable scaffold sizing Using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). J Am Coll Cardiol Intv 8 (2015), 1715–1726.
13. 13 Mintz, G.S., Nissen, S.E., Anderson, W.D., et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 37 (2001), 1478–1492.
14. 14 Inaba, S., Mintz, G.S., Farhat, N.Z., et al. Impact of positive and negative lesion site remodeling on clinical outcomes: insights from PROSPECT. J Am Coll Cardiol Img 7 (2014), 70–78.
15. 15 Mattesini, A., Secco, G.G., Dall'Ara, G., et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. J Am Coll Cardiol Intv 7 (2014), 741–750.
16. 16 Tsuchida, K., Garcia-Garcia, H.M., Ong, A.T., et al. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv 67 (2006), 188–197.
17. 17 von Birgelen, C., Gil, R., Ruygrok, P., et al. Optimized expansion of the Wallstent compared with the Palmaz-Schatz stent: on-line observations with two- and three-dimensional intracoronary ultrasound after angiographic guidance. Am Heart J 131 (1996), 1067–1075.
18. 18 Nakano, M., Wagatsuma, K., Iga, A., et al. Impact of highly asymmetric stent expansion after sirolimus-eluting stent implantation on twelve-month clinical outcomes. J Cardiol 49 (2007), 313–321.
19. 19 Vranckx, P., Kint, P.P., Morel, M.A., Van Es, G.A., Serruys, P.W., Cutlip, D.E., Identifying stent thrombosis, a critical appraisal of the academic research consortium (ARC) consensus definitions: a lighthouse and as a toe in the water. EuroIntervention 4 (2008), C39–C44.
20. 20 Claessen, B.E., Mehran, R., Mintz, G.S., et al. Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents. J Am Coll Cardiol Intv 4 (2011), 974–981.
21. 21 Witzenbichler, B., Maehara, A., Weisz, G., et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation 129 (2014), 463–470.
22. 22 Sonoda, S., Morino, Y., Ako, J., et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 43 (2004), 1959–1963.
23. 23 Chieffo, A., Latib, A., Caussin, C., et al. A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: the AVIO trial. Am Heart J 165 (2013), 65–72.
24. 24 Koskinas, K.C., Chatzizisis, Y.S., Antoniadis, A.P., Giannoglou, G.D., Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol 59 (2012), 1337–1349.
25. 25 Hwang, C.W., Wu, D., Edelman, E.R., Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104 (2001), 600–605.
26. 26 Papafaklis, M.I., Takahashi, S., Antoniadis, A.P., et al. Effect of the local hemodynamic environment on the de novo development and progression of eccentric coronary atherosclerosis in humans: insights from PREDICTION. Atherosclerosis 240 (2015), 205–211.
27. 27 Hong, S., Kim, B., Shin, D., et al. Effect of intravascular ultrasound–guided vs angiography-guided everolimus-eluting stent implantation: The ivus-xpl randomized clinical trial. JAMA 314 (2015), 2155–2163.